drug interactionsedoxabanP-glycoproteinpharmacokineticsAimsEdoxaban, a novel factor Xa inhibitor, is a substrate of cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). Three edoxaban drug-drug interaction studies examined the effects of P-gp inhibitors with varying degrees...
Table 1. Common Mechanisms of Drug-Drug Interactions MechanismDescriptionInteraction of DOACs With CYP450 Enzymes and Transporters ApixabanBetrixabanDabigatranEdoxabanRivaroxaban CYP450 enzymes 20%–25% metabolized by CYP3A4 <1% metabolized by CYP450 Not a substrate, inhibitor, or inducer of CYP450 enzym...
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine AimsEdoxaban, a novel factor Xa inhibitor, is a substrate of cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). Three edoxaban ... Parasrampuria,A Dolly,Mendell,... 被引量: 0发表:...
Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs Uptake transporters (e.g., members of the SLC superfamily of solute carriers) and export proteins (e.g., members of the ABC transporter superfamily) are im... K Sabine,MF Fromm,K J?Rg - 《Pharmaceutics》 被引量: 28...
Investigating Drug-Drug Interactions (DDIs) is crucial for optimizing drug treatments, improving therapeutic outcomes, and reducing adverse reactions, aiding in safer drug therapy strategies. Knowledge Graph Embedding (KGE) models, vital in DDI research, map drugs and their interactions in the Biomedica...
Valproate is the other of the two drugs that are known to cause major interactions with CBD. In addition to epilepsy, you can use valproic acid to treat some mental conditions and migraines. Valproic acid could cause severe, even life-threatening liver damage, usually within the first six mont...
(2022) Ferri et al. Pharmaceutics. The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, are becoming the most commonly prescribed drugs for preventing ischemic stroke in patients with non-valvular atrial fibrillation (
has many of the characteristics required to address unmet clinical needs: high oral bioavailability, a fast onset/offset of action, dose-dependent pharmacokinetics and pharmacodynamics, few drug–drug or drug–food interactions and, as a result of these, no requirement for routine coagulation ...
Lau, W. C. Y. et al. (2022, December 6). Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation. Retrieved fromhttps://www.acpjournals.org/doi/10.7326/M22-0511 ...
Dabigatran is not a substrate, inhibitor, or inducer of hepatic CYPs [75]. As less than 4% of the active metabolite of edoxaban is metabolised by CYP3A4 [76], drug interactions with CYP inducers or inhibitors are not expected. However, rivaroxaban and apixaban are CYP3A4 substrates; co-...